Evidence map›Paper›PMID 31555933›Full record

ArticleFamilial cancer2020

Novel candidates in early-onset familial colorectal cancer.

Anne M L Jansen, Pradipta Ghosh, Tikam C Dakal, Thomas P Slavin, C Richard Boland, Ajay Goel

Open access · greenAbstract read
In one paragraph

Article in Familial cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023
    Guideline
  2. Review
  3. Article
  4. Article
  5. Case Report: Expansion of theFrontiers in oncology · 2025
    Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Anne M L JansenCenter for Gastrointestinal Research, Center for Translational Genomics and Oncology, Baylor Scott & White Research Institute and Charles A. Sammons Cancer Center, Dallas, TX, USA.
Pradipta GhoshDepartments of Medicine and Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.
Tikam C DakalDepartment of Biotechnology, Mohanlal Sukhadia University, Udaipur, Rajasthan, 313001, India.
Thomas P SlavinDivision of Clinical Cancer Genomics City of Hope, Department of Medical Oncology, National Medical Center, Duarte, CA, USA.
C Richard BolandDepartments of Medicine and Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.
Ajay GoelCenter for Gastrointestinal Research, Center for Translational Genomics and Oncology, Baylor Scott & White Research Institute and Charles A. Sammons Cancer Center, Dallas, TX, USA. ajgoel@coh.org.ORCID 0000-0003-1396-6341
University of California San Diego · USBaylor Medical Center at Garland · USCity Of Hope National Medical Center · USMohanlal Sukhadia University · INTexas Oncology · US

Funding

The Biology and Diagnosis of HNPCCR01CA072851 · NCI · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI GOEL, AJAY · 1996 to 2019
$6.6M
Aspirin and Cancer Prevention in Lynch Syndrome: From Cell to Population DataU01CA187956 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI GOEL, AJAY, WODARZ, DOMINIK F · 2014 to 2018
$2.7M
MicroRNA Biomarkers for Determining Treatment Response in Colorectal CancerR01CA202797 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI GOEL, AJAY · 2016 to 2020
$1.9M
Development of microRNA Biomarkers For Noninvasive Detection of Colorectal CancerR01CA184792 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI GOEL, AJAY · 2015 to 2019
$1.8M
Modulation of G proteins by Growth FactorsR01CA160911 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA · 2013 to 2017
$1.8M
Mentored Clinical Scientist Research Career Development Award (Parent K08)K08CA234394 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI SLAVIN, THOMAS PAUL · 2018 to 2019
$498k
NCI NIH HHS K08 CA234394NCI NIH HHS R01 CA072851NCI NIH HHS R01 CA160911NCI NIH HHS R01 CA184792NCI NIH HHS R01 CA202797NCI NIH HHS U01 CA187956
6 · The paper itself

Abstract

In 20-30% of patients suspected of a familial colorectal cancer (CRC) syndrome, no underlying genetic cause is detected. Recent advances in whole exome sequencing have generated evidence for new CRC-susceptibility genes including POLE, POLD1 and NTHL1¸ but many patients remain unexplained. Whole exome sequencing was performed on DNA from nine patients from five different families with familial clusters of CRC in which traditional genetic testing failed to yield a diagnosis. Variants were filtered by minor allele frequencies, followed by prioritization based on in silico prediction tools, and the presence in cancer susceptibility genes or genes in cancer-associated pathways. Effects of frameshift variants on protein structure were modeled using I-Tasser. One known pathogenic variant in POLD1 was detected (p.S478N), together with variants in 17 candidate genes not previously associated with CRC. Additional in silico analysis using SIFT, PROVEAN and PolyPhen on the 14 missense variants indicated a possible damaging effect in nine of 14 variants. Modeling of the insertions/deletions showed a damaging effect of two variants in NOTCH2 and CYP1B1. One family was explained by a mutation in a known familial CRC gene. In the remaining four families, the most promising candidates found are a frameshift NOTCH2 and a missense RAB25 variant. This study provides potential novel candidate variants in unexplained familial CRC patients, however, functional validation is imperative to confirm the role of these variants in CRC tumorigenesis. Additionally, while whole exome sequencing enables detection of variants throughout the exome, other causes explaining the familial phenotype such as multiple single nucleotide polymorphisms accumulating to a polygenic risk or epigenetic events, might be missed with this approach.

Indexed as

Exome SequencingGenetic Predisposition to DiseaseAdolescentAdultAgedColorectal NeoplasmsCytochrome P-450 CYP1B1DNA Polymerase IIIFemaleFrameshift MutationGenes, NeoplasmHumansMaleMicrofilament ProteinsMiddle AgedMutation, MissenseCYP1B1 protein, humanCytochrome P-450 CYP1B1DNA Polymerase IIIMicrofilament ProteinsNOTCH2 protein, humanPOLD1 protein, humanRab25 protein, humanrab GTP-Binding ProteinsReceptor, Notch2SYNPO2 protein, humanCandidate variantsFamilial colorectal cancerPOLD1

Identifiers

PMID31555933
PMCPMC7241873
OpenAlexW2975482809

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.